BioInsights - Keys to the successful preclinical-clinical translation of next-gen CAR-T cell therapy

Keys to the successful preclinical-clinical translation of next-gen CAR-T cell therapy

Cell & Gene Therapy Insights 2022; 8(1), 29–38

10.18609/cgti.2022.004

Published: 8 February 2022
Interview
Devon J Shedlock

Devon J Shedlock, PhD, is Chief Scientific Officer, Cell Therapies at Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. He joined Poseida as its first employee in 2015 and most recently served as Senior Vice President of Research and Development. Dr Shedlock is a key scientific contributor in the application of the Company’s proprietary gene engineering platform technologies to develop novel cell therapy programs. Before joining Poseida, he held positions as an adjunct assistant professor of pathology and laboratory medicine at the Perelman School of Medicine and associate director of the T-Cell Engineering Laboratory that is part of Carl June’s group, both at the University of Pennsylvania. Dr Shedlock received his PhD in cell and molecular biology from the University of Pennsylvania, and a BS with Honors in biology from Ursinus College in Collegeville, Pennsylvania.